Charles & Colvard Value Stock - Dividend - Research Selection
Charles and colvard
ISIN: US1597651066 , WKN: 923940
Market price date:
Market price:
Market price:
Fundamental data and company key figures of the share
Annual reports in | |||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Key figures | |||||||||||||||||||||||||||||||||||||||||||||||||
Cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
Net operating cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
Capital Expenditures | |||||||||||||||||||||||||||||||||||||||||||||||||
Free cash flow | |||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet | |||||||||||||||||||||||||||||||||||||||||||||||||
Total Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
Liabilities & Shareholders equity | |||||||||||||||||||||||||||||||||||||||||||||||||
Income statement | |||||||||||||||||||||||||||||||||||||||||||||||||
Net income | |||||||||||||||||||||||||||||||||||||||||||||||||
Eps (diluted) | |||||||||||||||||||||||||||||||||||||||||||||||||
Diluted shares outstanding | |||||||||||||||||||||||||||||||||||||||||||||||||
Net sales/revenue |
Do you want to do make a detailed fundamental analysis of this stock?
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
Description | Data |
---|---|
Symbol | |
Market Capitalization | USD |
Country | |
Indices | |
Sectors | |
Raw Data Source | |
Stock Split | |
Internet |
Description of the company
Charles & Colvard, Ltd. manufactures, markets, and distributes moissanite jewels and finished jewelry featuring moissanite worldwide. The company offers near-colorless moissanite jewels cut in various shapes, including round, square brilliant, princess, cushion, radiant, pear, marquise, heart, and oval in sizes ranging from approximately 1.3 to 12 millimeters. It also provides finished jewelry featuring moissanite, such as stud earrings, solitaire and three-stone rings, pendants, and bracelets. The company primarily offers its products under the Charles & Colvard Created Moissanite, Forever Classic, Forever Brilliant, and Forever One brand names. It sells its products through distributors, manufacturers, retailers, television shopping networks, and designers, as well as at retail to end consumers through its direct-to-consumer e-commerce site, charlesandcolvard.com, third-party online marketplaces, drop-ship, and e-commerce outlets. Charles & Colvard, Ltd. was founded in 1995 and is based in Morrisville, North Carolina.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,
NEWS
Warning: CTHR is at high risk of performing badly
2023-02-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Charles & Colvard: What Starting My Own Moissanite Jewelry Business Taught Me
2023-02-15
Charles & Colvard specializes in the production and sale of moissanite jewelry. Now, so do I. See why my insights into CTHR stock make me rate it a Sell.
Bumbershoot Holdings 2022�� Investor Letter
2023-02-12
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.
Bumbershoot Holdings 2022 Investor Letter
2023-02-12
Bumbershoot Holdings registered a gain of +1.2% for the full-year 2022. What are our core messages and takeaways? Click here to find out.
Charles & Colvard, Ltd. (NASDAQ:CTHR) Q2 2023 Earnings Call Transcript
2023-02-06
Charles & Colvard, Ltd. (NASDAQ:CTHR) Q2 2023 Earnings Call Transcript February 2, 2023 Operator: Good afternoon and welcome to the Charles & Colvard, Ltd. Second Quarter Fiscal Year 2023 Earnings Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. This earnings call may contain […]
Charles & Colvard Ltd (CTHR) Reports Q2 Loss, Lags Revenue Estimates
2023-02-02
Charles & Colvard Ltd (CTHR) delivered earnings and revenue surprises of -200% and 5.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles & Colvard, Ltd. (CTHR) Q2 2023 Earnings Call Transcript
2023-02-02
Charles & Colvard, Ltd. (NASDAQ:NASDAQ:CTHR) Q2 2023 Earnings Conference Call February 2, 2023 4:30 PM ETCompany ParticipantsDon O'Connell - President and Chief Executive OfficerClint...
CHARLES & COLVARD REPORTS SECOND QUARTER FISCAL YEAR 2023 FINANCIAL RESULTS
2023-02-02
Charles & Colvard, Ltd. (Nasdaq: CTHR) (the "Company"), a globally recognized fine jewelry company specializing in lab created Made, Not Mined™ gemstones, reported financial results for the second quarter ended December 31, 2022 ("Second Quarter Fiscal 2023").
Charles & Colvard, Ltd. 2023 Q2 - Results - Earnings Call Presentation
2023-02-02
The following slide deck was published by Charles & Colvard, Ltd.
Charles & Colvard GAAP EPS of -$0.03 misses by $0.02, revenue of $10.4M misses by $0.6M
2023-02-02
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.